Medexus Pharmaceuticals

Regulatory Pressure Will Limit Revenues While Allowing Cautious Recovery

AnalystLowTarget

Not Invested

Community Contributor

Published

26 Jul 25

AnalystLowTarget's Fair Value

CA$5.55

50.8% undervalued

04 Sep

CA$2.73

9.2%

-2.2%

9.2%

-2.2%

You can edit this narrative until Jul 26 10:25 PM. Then, changes will post as Updates.

Author's Valuation

CA$5.5550.8% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

CA$5.55

50.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

11.62%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.97%

Calculation

US$32.27m

Earnings '28

10.51x

PE Ratio '28

US$339.22m

Market Cap '28

US$339.22m

Market Cap '28

70.87m

No. shares '28

US$4.79

Share Price '28

US$4.79 Share Price '28

Discounted to 2025 @ 5.97% p.a.

US$4.02

Fair Value '25

US$4.02 Fair Value '25

Converted to CAD @ 1.3799 USD/CAD Exchange Rate

CA$5.55

Fair Value '25